Literature DB >> 35399308

Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.

Kyohei Watanabe1, Keita Tamura1, Yuto Matsushita1, Hiromitsu Watanabe1, Daisuke Motoyama1, Toshiki Ito1, Takayuki Sugiyama1, Atsushi Otsuka1, Hideaki Miyake1.   

Abstract

Background/Aim: Transurethral resection of bladder tumors (TURBT) guided by photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) has been shown to be superior to conventional white light (WL) cystoscopy with regard to diagnostic accuracy, for non-muscle invasive bladder cancer (NMIBC); however, PDD is usually performed prior to WL TURBT. The objective of this study was to investigate the diagnostic significance of 5-ALA-mediated PDD following TUR of NMIBC. Patients and
Methods: In 83 NMIBC patients, all visible tumors were completely resected under the conventional WL guidance followed by additional resection if fluorescent lesions were observed under the blue light (BL) guidance, and random biopsy was further conducted.
Results: With the BL source, 39 (47.0%) patients were judged to have fluorescent lesions. Twenty (51.3%) of the 39 patients with positive findings by PDD were diagnosed with residual cancer by additional resection, while random biopsy detected cancers in 2 (4.5%) of the 44 patients with negative findings by PDD. Accordingly, the sensitivity, specificity, positive predictive value and negative predictive value in diagnosing residual cancer by our PDD system were 90.9, 68.9, 51.3 and 95.5%, respectively. Univariate analysis showed that the presence of residual cancers shown by WL TURBT was significantly associated with the preoperative findings of urinary cytology, tumor multiplicity, pathological T stage and tumor grade, of which only the preoperative finding on urinary cytology was shown to have an independent impact on the diagnosis of residual cancer.
Conclusion: 5-ALA-mediated PDD following standard WL TURBT could improve the diagnostic accuracy in NMIBC patients, particularly those who are positive for preoperative urinary cytology. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  5-aminolevulinic acid; Photodynamic diagnosis; non-muscle invasive bladder cancer; transurethral resection of bladder tumors

Year:  2021        PMID: 35399308      PMCID: PMC8962795          DOI: 10.21873/cdp.10027

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  19 in total

Review 1.  Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review.

Authors:  Piotr Kutwin; Tomasz Konecki; Marcin Cichocki; Piotr Falkowski; Zbigniew Jabłonowski
Journal:  Photomed Laser Surg       Date:  2017-05-22       Impact factor: 2.796

2.  Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence.

Authors:  M Kriegmair; R Baumgartner; R Knüchel; H Stepp; F Hofstädter; A Hofstetter
Journal:  J Urol       Date:  1996-01       Impact factor: 7.450

Review 3.  The natural history of bladder cancer. Implications for therapy.

Authors:  R Lee; M J Droller
Journal:  Urol Clin North Am       Date:  2000-02       Impact factor: 2.241

4.  Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Tsutomu Shimamoto; Masayuki Kamada; Tatsuo Iiyama; Mitsuhiko Miyamura; Atsushi Kurabayashi; Mutsuo Furihata; Masanobu Tanimura; Hironobu Watanabe; Taro Shuin
Journal:  Cancer       Date:  2011-07-19       Impact factor: 6.860

5.  Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.

Authors:  Iori Sakai; Hideaki Miyake; Ken-Ichi Harada; Isao Hara; Taka-Aki Inoue; Masato Fujisawa
Journal:  Int J Urol       Date:  2006-11       Impact factor: 3.369

6.  Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.

Authors:  Martin Kriegmair; Dirk Zaak; Karl-Heinz Rothenberger; Jens Rassweiler; Dieter Jocham; Ferdinand Eisenberger; Roland Tauber; Arnulf Stenzl; Alfons Hofstetter
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

7.  Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.

Authors:  Yasushi Nakai; Keiji Inoue; Toyonori Tsuzuki; Tsutomu Shimamoto; Taro Shuin; Kazuhiro Nagao; Hideyasu Matsuyama; Masafumi Oyama; Hiroshi Furuse; Seiichiro Ozono; Makito Miyake; Kiyohide Fujimoto
Journal:  Int J Urol       Date:  2018-07-12       Impact factor: 3.369

8.  Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.

Authors:  Zafer Tandogdu; Rebecca Lewis; Anne Duncan; Steven Penegar; Alison McDonald; Luke Vale; Jing Shen; John D Kelly; Robert Pickard; James N Dow; Craig Ramsay; Hugh Mostafid; Paramananthan Mariappan; Ghulam Nabi; Joanne Creswell; Henry Lazarowicz; John McGrath; Ernest Taylor; Emma Clark; Graeme Maclennan; John Norrie; Emma Hall; Rakesh Heer
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

9.  A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging.

Authors:  Joo Yong Lee; Kang Su Cho; Dong Hyuk Kang; Hae Do Jung; Jong Kyou Kwon; Cheol Kyu Oh; Won Sik Ham; Young Deuk Choi
Journal:  BMC Cancer       Date:  2015-08-01       Impact factor: 4.430

10.  Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis.

Authors:  Changhao Chen; Hao Huang; Yue Zhao; Hao Liu; Richard Sylvester; Tianxin Lin; Jian Huang
Journal:  BMJ Open       Date:  2019-10-17       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.